Oxprenolol in Myocardial Infarction Survivors: Brief Review of the European Infarction Study Results in the Light of Other Beta-Blocker Post Infarction Trials

  • R. Schröder
Conference paper


The European Infarction Study (EIS) was a multicentre, double-blind, randomized study comparing the effect on survival, cardiac mortality and non-fatal cardiac events of oxprenolol slow release 160 mg b.i.d. with placebo in 1741 patients aged 35 to 69 years surviving acute myocardial infarction. During the one year follow-up there was a 30% difference in the cumulative mortality rate in favor of placebo. In the oxprenolol group the mortality was noted to be higher in patients who were 65–69 years of age. In general, there was a higher incidence of fatal reinfarctions and of sudden death in those, who discontinued study medication.

24-h ECG recordings before randomization in 736 patients revealed a high prevalence of complex ventricular tachydysrhythmias. These patients had a significantly higher one-year mortality. Like other beta-blocking drugs oxprenolol had a weak suppressant effect on ventricular tachydysrhythmias in infarct survivors. The proportion of deaths was noted to be higher in the oxprenolol group to the same relative degree in patients with or without complex tachydysrhythmias.

Reviewing the results of other beta-blocker post infarction trials it is concluded that a protective effect on sudden death in myocardial infarction survivors is related to beta-blockade. Beta-blocking drugs with significant intrinsic sympathomimetic activity, which partly counteracts beta-blockade, might be less effective. High dose oxprenolol treatment might be deleterious to some patients with more enhanced coronary heart disease.


Acute Myocardial Infarction Multicenter International Study Myocardial Infarction Survivor Discontinue Study Medication Norwegian Multicentre Study Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. A Multicentre International Study (1975) Improvement in prognosis of myocardial infarction by long-term beta-adrenoceptor blockade using practolol. Br Med J: 735–740Google Scholar
  2. Anderson MP, Bechsgaard P, Fredericksen J, Hansen DA, Jürgensen HJ, Nielsen B, Pedersen F, Pedersen-Bjergaard O, Rasmussen SL (1979) Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction. Lancet ii: 865–868CrossRefGoogle Scholar
  3. Australian and Swedish Pindolol Study Group (1983) The effect of pindolol on the two years mortality after complicated myocardial infarction. Eur Heart J 4: 367–375Google Scholar
  4. Baber NS, Wainwright Evans D, Howitt G, Thomas M, Wilson C, Lewis J A, Dawes PM, Handler K, Tuson R (1980) Multicentre post-infarction trial of propranolol in 49 hospitals in the United Kingdom, Italy and Yugoslavia. Br Heart J 44:96–100PubMedCrossRefGoogle Scholar
  5. Baber NS, Lewis JA (1980) Beta-blockers in the treatment of myocardial infarction. Br Med J 2: 59 (abstr)CrossRefGoogle Scholar
  6. Barber JM, Boyle DMcC, Chaturvedi NC, Singh N, Walsh MJ (1976) Practolol in acute myocardial infarction. Acta Med Scand 587 (Suppl): 213–216Google Scholar
  7. β-blocker Heart Attack Trial Research Group (1982) A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247:1707–1714CrossRefGoogle Scholar
  8. Biamino G, Schroder R (1983) What is the real pharmacological rationale for beta-receptor blocking agents? Eur Heart J 4 (Suppl D): 137–141PubMedGoogle Scholar
  9. Bigger JT (1985) Risk stratification after myocardial infarction. Z Kardiol 74: Suppl 6:147–157PubMedGoogle Scholar
  10. Die Europäische Infarktstudie (1985) Die Bedeutung der quantitativen Analyse von ventrikulären Rhythmusstörungen für die Prognose von Patienten mit Zustand nach Myokardinfarkt. Z Kardiol 74:97 (abstr 345)Google Scholar
  11. Hampton JR (1981) The use of beta blockers for the reduction of mortality after myocardial infarction. Eur Heart J 2:259–268PubMedGoogle Scholar
  12. Hansteen V, Moinichen E, Lorentsen E, Andersen A, Strom O, Soiland K, Dyrbekk D, Refsum A-M, Tromsdal A, Knudsen K, Eika C, Bakken J, Smith P, Hoff PI (1982) One year’s treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. Br Med J 284:155–161CrossRefGoogle Scholar
  13. Harrison DC (1983) Beneficial effects of beta blockers: A class action or individual pharmacologic spectrum? Circulation 67–1:77–82Google Scholar
  14. Hjalmarson A, Elmfeld D, Herlitz J, Holmberg S, Malek I, Nyberg G, Ryden L, Swedberg K, Vedin A, Waagstein F, Waldenstrom A, Waldenstrom J, Wedel H, Wilhelmsen L, Wilhelmsson C (1981) Effect on mortality of metoprolol in acute myocardial infarction. Lancet ii: 823–827CrossRefGoogle Scholar
  15. Julian DG, Jackson FS, Prescott RJ, Szekely P (1982) Controlled trial of Sotalol for one year after myocardial infarction. Lancet May 22:1142–1147CrossRefGoogle Scholar
  16. Lichstein E, Morganroth J, Harrist R, Hubble E, for the BHAT Study Group (1983) Effect of propranolol on ventricular arrhythmia. The Beta-blocker Heart Attack Trial Experience. Circulation 67–1: 5–10Google Scholar
  17. Manger Cats V, van Capelle FJL, Lie KI, Durrer D (1983) Antiarrhythmic effects of metoprolol in the post-hospital phase of myocardial infarction. Circulation 68–111:275 (abstr)Google Scholar
  18. Manning AS, Hearse DJ, Coltart DJ (1982) Effect of chronic β-blockade on the ischaemic myocardium: a comparative study with five drugs. J Cardiovasc Pharmacol 4:999–1005PubMedCrossRefGoogle Scholar
  19. Mukhariji J, Rude RE, Poole WK, Gustafson N, Thomas LJ, Strauss HW, Jaffe AS, Muller JE, Roberts R, Raabe DS, Croft CH, Passamani E, Braunwald E, Willerson JT, and the Milis Study Group (1984) Risk factors for sudden death after acute myocardial infarction: Two-year followup. Am J Cardiol 54:31–36CrossRefGoogle Scholar
  20. Multicenter International Study (1975) Improvement in prognosis of myocardial infarction by long-term beta-adrenoceptor blockade using practolol. Br Med J 3:735–740CrossRefGoogle Scholar
  21. Nadamanee K, Singh B, Hendrickson J, Rollett E (1983) Efficacy of three β-antagonists in suppressing premature ventricular contraction: Relevance of mechanism of sudden death reduction in survivors of myocardial infarction. JACC 1 (2): 719 (abstr)Google Scholar
  22. Ollson G, Rehnquist N (1984) Ventricular arrhythmias during the first year after acute myocardial infarction: influence of long-term treatment with metoprolol. Circulation 69:1129–1134CrossRefGoogle Scholar
  23. Roden DM, Wang T, Woosley RL (1984) Antiarrhythmic effects of β-blocking drugs. In: Lucchesi BR, Dingell JV, Schwarz RP (eds) Perspectives in cardiovascular research, Volume 10. Raven Press, New York, pp 95–103Google Scholar
  24. Rose G (1982) Prophylaxis with β-blockers and the community. Br J Clin Pharmacol 14:45S-48SPubMedGoogle Scholar
  25. Ryden L, Ariniego R, Arnaman K, Herlitz J, Hjalmarson A, Holmberg S, Reyes C, Smedgard P, Svedberg K, Vedin A, Waagstein F, Waldenstrom A, Wilhelmsson C, Wedel H, Yamamoto M (1983) A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. New Engl J Med 308: 614–618PubMedCrossRefGoogle Scholar
  26. Shand DG (1983) Clinical pharmacology of the beta-blocking drugs: Implications for the postinfarction patient. Circulation 67–1: 2–5Google Scholar
  27. Singh BN, Venkatesh N (1984) Prevention of myocardial reinfarction and of sudden death in survivors of acute myocardial infarction: Role of prophylactic β-adrenoceptor blockade. Am Heart J 107:189–200PubMedCrossRefGoogle Scholar
  28. The European Infarction Study Group (1983) Ventricular tachyarrhythmias, β-blocker treatment and mortality after myocardial infarction. Eur Heart J 4 (Suppl E): 57 (abstr)Google Scholar
  29. The European Infarction Study Group (1984a) Failure of β-blocker treatment to suppress ventricular dysrhythmias in survivors of myocardial infarction. JACC 3 (2): 576 (abstr)Google Scholar
  30. The European Infarction Study Group (1984b) European Infarction Study (EIS) A secondary prevention study with slow release Oxprenolol after myocardial infarction: Morbidity and mortality. Eur Heart J 5:189–202Google Scholar
  31. The European Infarction Study Group (1985 a) Effect of Oxprenolol on ventricular arrhythmias. The European Infarction Study Experience. JACC 6 (5): 963–972Google Scholar
  32. The European Infarction Study Group (1985 b) Unwanted side-effects of oxprenolol in myocardial infarction survivors (in preparation)Google Scholar
  33. The Norwegian Multicentre Study Group (1981) Timolol-induced reduction in mortality and rein-farction in patients surviving acute myocardial infarction. N Engl J Med 304: 801–807CrossRefGoogle Scholar
  34. Wilcox RG, Rowley JM, Hampton JR, Mitchell JRA (1980 a) Randomised placebo-controlled trial comparing oxprenolol with disopyramide phosphate in immediate treatment of suspected myocardial infarction. Lancet October 11: 765–769Google Scholar
  35. Wilcox RG, Roland JM, Banks DC, Hampton JR, Mitchell JRA (1980b) Randomised trial comparing propranolol with atenol in immediate treatment of suspected myocardial infarction. Br Med J March 29: 885–888CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin, Heidelberg 1987

Authors and Affiliations

  • R. Schröder
    • 1
  1. 1.Department of Cardiology and Pneumonology, Klinikum SteglitzFree University BerlinWest Germany

Personalised recommendations